LV12861B - Imūnstimulators ar pretaudzēja aktivitāti un tā iegūšanas paņēmiens - Google Patents

Imūnstimulators ar pretaudzēja aktivitāti un tā iegūšanas paņēmiens Download PDF

Info

Publication number
LV12861B
LV12861B LVP-02-108A LV020108A LV12861B LV 12861 B LV12861 B LV 12861B LV 020108 A LV020108 A LV 020108A LV 12861 B LV12861 B LV 12861B
Authority
LV
Latvia
Prior art keywords
culture
enterovirus
cancer
stem
6ojibhbix
Prior art date
Application number
LVP-02-108A
Other languages
English (en)
Inventor
Aina Muceniece
Original Assignee
Aina Muceniece
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aina Muceniece filed Critical Aina Muceniece
Priority to LVP-02-108A priority Critical patent/LV12861B/lv
Publication of LV12861B publication Critical patent/LV12861B/lv
Priority to EA200500014A priority patent/EA007839B1/ru
Priority to TR2018/09382T priority patent/TR201809382T4/tr
Priority to ES03733607.0T priority patent/ES2678053T3/es
Priority to EP03733607.0A priority patent/EP1537872B1/en
Priority to AU2003241866A priority patent/AU2003241866A1/en
Priority to PCT/LV2003/000006 priority patent/WO2003105875A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32333—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32361—Methods of inactivation or attenuation
    • C12N2770/32364—Methods of inactivation or attenuation by serial passage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Description

LV 12861 ΜΜΜΥΗΟΟΤΜΜΜΛΤΟΡ ΠΡΟΤΜΒΟΟΠΥΧΟ/ΙΕΒΟΓΟ flEMCTBHfl Μ CTIOCOB ΕΓΟ ΠΟ/ΙΥΗΕΗΜΑ npeanaraeMoe ΗβοβρβτβΗΗβ othochtch k o6jiacTH MejiHUHHbi, b ηβοτηοοτη k npenapaTaM aKTHBHOīi HMMyHOTepariHH 3JiOKaHecTBeHHbix HOBoo6pa30BaHHH, HanpnMep, MejiaHOMbi, a TaioKe κ cnocoSaM nojiyHeHna 3thx npenapaTOB. B HacTonmee BpeMa H3BecTeH HMMyH0CTHMyji«T0p, npenCTaBjunomHH co6oh ΒΒΟΛΗγΚ) CMeCb KJieTOMHbIX ΚΟΜΠΟΗβΗΤΟΒ, COflep)KaiHHX paKOBbie aHTHreHbl H HCTOHHHK hohob MapraHua (naT. BejiHKo6pHTaHHH JVs 1592496 ot 24. 11.77 h naT. OpaHUHH Ns 2423223 ot 20.05.79. no M.kji.3 A61K 39/00).
TaKOH HMMyHOCTHMyjWTOp 3φφβΚΤΗΒβΗ B HaHaJIbHOH CTa^HH 3a6ojieBaHHH HJIH πρκ ocraTOHHOM jieneHnn, Koraa hhcjio KJieTOK, ocTaBumxca nocjie nepBoro jienemui, HeBejiHKO.
OflHaKO, ecjiH o6pa6aTbiBaeTca 3aMeTHaa onyxojib, to HHbeiojHfl momcct 0Ka3aTbca 6ecnojie3HOH, a bo3mojkho aaace Bpe/jHoft, yBejiHHHBaiomeH KOJinnecTBO φφκγπκργιοιίίΗχ co6cTBeHHbix onyxojieBbix aHTHreHOB, 6jiOKHpyiomHx HMyHHbie κπβτκΗ.
B03M0>KH0CTH npHrOTOBJTeHHH Cnem^HHHbDC BāKIIHH H3 HHflHBH,OyaJIbHbIX onyxojieH HejioeeKa orpaHHHeHbi KaK ΒρβΜβΗβΜ, TaK h kojihhcctbom MaTepnajia. H3BecTHbi TaioKe HMMyHHocTHMyjiHpyiouzHe azibfOBaHTbi, conepJKauiHe nepBHHHbifi aHTHreH y6HToro uiTaMMa B.Pertussis NRRL-11,232, coeaHHeHHoro coHeraioiiiHM areHTOM flHH30unaHaTOM co BTOpbiM aHTHreHOM H3 >KHBbix KjieroK afleHOKapijHHOMbi (naT. CIIIA N° 4285930 OT 13.11.79. no M.kji.3 A61K 39/12). ΠρΗΜβΗβΗΗβ aaHHbrc CTHMyjwTopoB noBbimaeT οφφβκτ KOMnjieKCHOH TepanHH. B to ace epeMH πρπΜβΗβΗΗβ npenapaTOB 3τογο Tnna conpOBOJKnaeTca πο6ομηημη οφφβκτΒΜϋ KaK jioKajībHoro, Tax h o6mero xapaicrepa: BocnajiHTejibHbie rpaHyjiOMbi, H3Bbi, 1ΙΗΜφθΑβΗΟΠ3ΤΗ5Ι, JlBJieHHe rnnepHyBCTBHTeJIbHOCTH H Τ.Π. H3 HHCjia H3BecTHbix HanGojiee 6jih3ok 3aaBjmeMOMy HMMyHOCTHMyjiaTopy KjieTOHHoro HMMyHHTeTa npoTHBOonyxojieBoro jiencTBua, conepacainnH arreHyHpoBaHyio BHpycHyio KyjibTypy BaKijHHbi ceMeficTBa Vaccinia vīrus AS ATCC No VR 2010 (naT. CIIIA .No 4315914 ot 04.04.80. M.kji.3 A61K 45/05). 2 H3BecTHbiii n\iMyHOCTHMyjiKTop nojiyMaiOT πγτβΜ BbiaeJieHHH anaToreHHoro BHpyca ocnoBaKiļHHbi, pa3MHO»eHHH ero b mohocjiohhoh KyjibType ιαιετοκ 3M6pHOHa UbinjieHKa, nocjie naccHBHpoBaHHa ero b mohocjiohhoh KyjibType ιαιβτοκ ποπβκ Kpbicbi. jļaHHbifi HMMyHOCTHMyjiHTop ΗΒϋΗβτοΗ HanSojiee SojibiiiHM, CTpyKTypHO h aHTHreHHO cjiojkho ycTpoeHHbiM /ļHK-reHOMHbiM BHpycoM, npeflCTaBjiaiomHM co5oh nojiHKjiOHajībHbiH CTHMyjiHTOp HMyHHofi CHCTeMbi, npeHMymecTBeHHo aeHCTByiomHH Ha KJieTOHHblH HMMyHHTer. npH flJIHTejIbHOM napeHTepaJIbHOM ΠρΗΜβΗβΗΗΗ H3BeCTHOrO HMMyHOCTHMyjWTOpa B03HHKai0T pa3JIHHHbie no6oHHbie οφφβΚΤΗ, B HaCTHOCTH, peaKLIHH rHnepHyBCTBHTejibHOCTH, xapaKTepHbie η ujih 6aicrepHajibHbix HecnenH(ļ)HHHbix HMMyHOCTHMyjLHTOpOB. IIo6oHHbie οφφβκτΜ CHH^aioT 3φφβκτΗΒΗοσπ> πρΗΜβΗβΗΗΗ npenapaTa πρπ noziaBjieHHH pa3BHTna onyxojiH, B03HHKaiomeH nocjie onepauHH. B pase cjiynaeB aaHHbie 3φφβκτΜ eoo6me nejiaiOT πρΗΜβΗβΗΗβ H3BecrHoro npenapaTa η6βο3μο>κημμ. IļejibK) HacToainero Η3θ6ρβτβΗΗΗ aBjmeTca noBbiuieHHe 3φφ6ΚΤΗΒΗ0(ηΉ nozīaBJieHHa pocTa onyxojiH, B03ηηκβιοmeii nocjie onepaunn, npn zuiHTēJībHOM ΠρΗΜβΗβΗΗΗ,
CorjiacHO H3o6pereHHio, nocTaBjieHHaa uejib aocTHraercs τβΜ, hto b HMMyHocTHMyjiaTope npoTHBOonyxojieBoro itencTBua, BKJuonaiomeM anaToreHHyio BHpycHyio KyjibTypy, b KanecTBe ee Hcnojib3yiOT aaaiiTHpoBaHHbiH κ onyxojiH urraMM 3HTepoBHpycoB Picomaviridae Enterovirus mna ECHO, BbmejieHHbiii H3 KHUieHHHKa HeaoBeKa c τκτροΜ Ha mohocjiohhoh KyjibType φπ6ρο6ιΐ3θτοΒ 3M6pnoHa nenoBeKa paBHbiM 5 - 7 lg ΤΙ1ΖΪ50/0,1 mji. U,ejib Η3θβρβτβΗΗΛ nocTHraeTca TaioKe 3a επετ τογο, hto b cnoco6e nojiyHeHna HMMyHOCTHMyjiHTopa nyTeM BbinejieHHa anaToreHHofi BnpycHOH KyjibTypbi, naccHBHpoBaHHa ee b mohocjiohhoh KyjibType ιαιετοκ c nocjienyiomHM ee pa3MHoaceHHeM b mohocjiohhoh KyjibType ιαιετοκ h OTjiejieHHeM pa3MHoaceHHofi BHpycHoft KyjibTypbi, anaToreHHyio KyjibTypy 3HTepOBHpycoB BbinejunoT H3 KHiueHHHKa nejiOBena, OT6npaioT BHpycHyio KyjibTypy, HMeioinyio cponcTBO κ onyxojiH, a naccHBHpoBaHHe npoBoajrr Ha onyxojieBbix τκβηηχ pa3JiHHHbix 6ojibHbix, nocjie Hero npoBOznrr pa3MHO>KeHHe naccHBHpoBaHHoro uiTaMMa Ha KyjibType φΗδροβϋΒστοΒ 3M6pHOHa nejiOBeKa ao mrpa 5 -7 lg TH£ 50/0,1 mji. 3HTepoBnpyc rpynnbi ECHO ceMencTBa Picomaviridae Enterovirus othochtch k Han6ojiee npocrbiM ΡΗΚ-γθηομημμ BnpycaM. Oh HMeer TOJibKO 4 CTpyicrypHbix 3 LV 12861 nojiHnenTHfla h cooTBercrBeHHO MeHbmee koahhcctbo aHTHreHHbix Αετβρμηηβητ (aKTHBHbCC ueHTpOB) flJIH B3aHMOAeHCTBHA C pa3JIHHHbIMH KJIOHaMH HMMyHOKOMnereHTHbIX KJieTOK. flaHHblH HMMyHOCTHMyjIBTOp HBJlHeTCH CTHMyjWTOpOM npCHMyiU6CTB6HHO ryMopajibHoro 3BeHa HMMyHHTera (β-κΑβτκκ) c npoTHBOonyxoaeBbiM aeHCTBHeM. OyHKUH0HajibHaa aKTHBHOCTb β-κΑετοκ nopaacaerca npH ηηλυιοϊηη onyxojieBoro npouecca paHbtiie, neM y Τ-κΛβτοκ.
CoBOKynHOCTb OTjiHHHTejibHbix npH3HaKOB cnoco6a no3BOJiaer anarrrHpoBaTb BbmeaeHHyio anaToreHHyio KyjibTypy 3HTepoeHpycoB κ onyxojieBbiM τκβηαμ pa3JiHHHbiM 6ojibHbiM h o6ecneMHTb ee pa3MHOxceHHe. Πρκ raTpe BHpyca HH^ce 5 lg Tlļiļ 50/061 mji 3φφεκτ nMMyHOCTHMyjiHtļHH He Ha6AK>AaeTCJi, t.k. aKTHBHOCTb KyjibTypbi caa6a. ΠρΗ THTpax Bbirne 7 lg Tlļ/ļ 50/061 mji Ha6jnoaaerca chhjkchhc aKTHBHOCTbH KyjibTypbi.
H3 KHUieHHoro Tpaicra JHOAefi, npeHMymecTBeHHO 3AOpOBbix Aereft b B03pacre 2-5 ηετ, BbiAejiKHiOT KHineHHbie BHpycbi Ha nepBHHHOH KyAbType 3M6pnoHa nejiOBeKa. 3aTeM OT6HpaiOT anaToreHHbie cepojioranecKMe τηπμ 3HTepoBHpycoe Picomaviridae Enterovirus THna ECHO, HanpHMep ECHO-7. Jļnsi BbiAeJieHHa BHpyca HcnoAb3yiOT φβΚΒΑΗΗ. IIoCAe BblASACHHH HCXOAHOH KyjIbTypbI OīIpeACJIAKDT ee OHKOTponH3M K MeAaHo6AacrroMe hah Apyr«M onyxojiHM, HcnoAb3ya κοροτκοοροκΗΟ nepe>KHBaK)myio KyAbTypbi onyxoAH. OTo6paHHyio KyAbTypy aAarrrHpyioT naccHBHpoBaHHeM Ha onyxojieBbix τκεηαχ MeAaH06AaCT0MbI pa3AHHHbIX 60AbHbIX ZUIH yCHAeHHA ΟΠβΗΗφΗΗΗΟΟΤΗ A6HCTBHA.
IlaccHBnpoBaHHbiH uiTaMM pa3MHO>KaiOT Ha KyjibType Φη6ρο6α3(πόβ 3M6pHOHa HeAOBeKa ao THTpa 5 - 7 lg 1112(50/061 ma. HHAce npHBOAHTCH AeTaAbHoe onncaHHe cnoco6a.
HcxoAHyio anaToreHHyio KyAbTypy Picomaviridae Enterovirus THna ECHO, HanpHMep, ECHO-7, BbiAenaioT H3 KHiueHHHKa 3AopoBbix ΑβτβΗ b B03pacre 2-5 Αετ. /1jia nepBHHHoro BbiAeAeHHH HcnoAb3yioT φεκΒΑΒΗΜβ npo6bi. npo6y b CTepHAbHOM φAaκoHe ΗβΜβΑΑβΗΗΟ noMemaiOT b χοαοαηαβηηκ πρκ TeMnepaType -10°C. /Ļia BbmeAeHHA BnpycoB HcnoAb3yiOT 20% B3Becb MaTepnajia b pacTBope XeHKca. B3Becb ^eHτpHφyΓHpyκ>τ πρκ 3000 o6/mhh b TeneHHe 30 mhh. HaAOcaAOMHyio jkhakoctL· 3aMopajKHBaioT h BbinepjKHBaiOT npH 3toh TeMnepaType b TeneHHe 24 nacoB. 3aTeM cycneH3Hio OTTaneaiOT, Ao6aBjraioT 3ητη6ηοτηκη: neHHUHAAHH - 1000 θαμημη/μα, 4 CTperiTOMHijHH - 250 eaHHHu/Ma h Bbiziep>KHBaK)T b τβπβΗΗβ 1 - 2 nacoB. ΠοΛγΜβΗΗγιο B3Becb ποΒτορΗΟ ΗβΗτρΗφγπιργκ>τ 1 - 2 pa3a npH 3000 o6/mhh b τβΗβΗΗβ 30 mhh. HaaocaaoHHaa acHaKOCTb nocae προΒβρκκ Ha CTepHjībHocrb BHOBb 3aMopa>KHBaeTCH h Bbwep>KHBaeTCJi npn TeMnepaType /-10°C/ -/-20°C/. riojiyHeHHbiM BHpycocoaep)KamHM MaTepnaaoM ΗΗφκΐίΗργιοτ mohocjiohhoh TpHnCHHH3HpOBHHOH KyjIbTypbI φπ6ρθ6Λ30ΤΟΒ 3M6pHOHa HejlOBeKa. riOOTepjKHBaiOmaa cpeaa xuia ηηΦηι1μροββηημχ KyabTyp npeacTaBaaeT co6oh cpeay 199 h 2% TejiflHbefi CbiBopoTKH, HaHajībHaH - cpeaa 199 h 10% TeaHHben cbieoponcr. nocae KOHTaicra c KjierKaMH b τβπβΗΗβ οληογό naca, oTcacbiBaiOT cycneH3Hio h xio6aBjTXK)T noaaep5KHBajomyio cpeay. ^ajiee προβκρκΗ c κπθτκβμη ΜΗκγβπργιοτ πρπ 37°C b τβΗβΗΗβ 2-10 ΛΗβπ. B τβΗβΗΗβ 3τογο ΒρβΜβΗΗ προΒΟΛΗτ 2-3 nocaeaoBaTeabHbix naccajKa MaTepnaaa b KyjibType φΗ6ρο6ϋ3βτθΒ 3M6pHOHa HeaoeeKa. ΠρΗ Ka»caoM naccaace βροκ HHKy6auHH προδπροκ aanTca ao ποιιηοη aereHepaiļHH κχιβτοκ. Ποβιτβ BbiaejieHRH uHTonaToreHHoro BHpyca noayHeHHbm Marepnaa noaBepraerca THTpOBaHHK) Η ββρΟϋΟΓΗΗββΚΟΜγ THĪIHpOBaHHK).
Bnpyccoaep>KamHH MaTepnaa οβΒβτπχιοτ ιχβΗτρΗφγτΗροΒ3ΗΗβΜ npH 3000 o6/mhh. B ΤβΗβΗΗβ 20 MHHyT, 3aMOpa>KHBafOT H XpaHflT ΠρΗ ΤβΜΠβρϊίγρβ /-20°C/ - /-70°C/. Τπτρ BHpyca b KyjibType φΗ0ρο6π3βτοΒ 3M6pnoHa HeaoeeKa cocTaBjiaeT 5 - 7 lg TUZJ50/0,1 mji. nocae BbiaeaeHHa ιιιτβμμοβ BHpyca onpeaeaaiOT ηχ ΟΗκοτροπκβΜ b ycaoBHax nepejKHBaK»mHx KyabTyp onyxoaen.
Jlnn aaanTauHH BbiaeaeHHofi BHpycHOH xyabTypbi Hcnoab3yiOT onyxoaeebie TKaHH, noayneHHbie npH onepaunn ot pa3aHHHbix 6oabHbix, Ηβ noaBepraBuiHxcx KaKofi-anGo TepanHH. Onyxoaeeaa TKaHb OHHmaeTca ot >khpoboh TKaHH, ΗβκροτΗΗββκπχ onaroe h κροΒΗ. 3aTeM oHHiaeHHyio onyxoaeByio TKaHb BbiaepacHBaioT b τβΗβΗΗβ 18-20 nacoB npH TeMnepaType 0°C, nocae nero ee pa3MeabHaioT Ha κγοοπκπ pa3MepoM 0,1 - 0,2 Ma, noMemaioT b nHTaTeabHyio cpeay 199, nan nHTaTeabHyio cpeay Hraa 5β3 βΗΒοροτκπ (100 μγ TKaHH Ha 4 Ma riHTaTeabHOH cpeabi). TKaHb ΗΗφΗΐιπργιοτ BHpycHOH KyabTypofi 105 - 106 TlļH 50 h noMemaioT b TepMOCTaT npn TeMnepaType 37°C 6β3 aonoaHHTeabHofi noaaHH yraeKHCaoro ra3a. Ε)κβΛΗβΒΗθ 33ΜβΗΛΚ)τ no 5 Ma βΒβ>κβΗ nHTaaTeabHofi cpeaofi. KyabTHBnpoBaHHe npeKpamaiOT npH aocTHJKeHHH rH6eaH κγςοπκοβ onyxoaH, KOTopaa onpeaeaaerca MopφoaoΓHHecκH h BH3yaabHO no OKHcaeHHK) cpeabi. 5 LV 12861
Jlpn onpeaejieHH» HmreHCHBHOCTH pa3MHO>KeHHJi τΗτργιοτ BHpyc b hchakoh φβ3β KyjibTypbi onyxoJiH, co6HpaeMoii βίκβΛΗββΗΟ HHTeHCHBHOCTb penponyKUHH B«pycoB oueHHBaiOT npw noncnere npoueHTa BbiuBJieHHoro b 3apaxceHHOH TKaHH BHpyca no OTHOUieHHK) K A03e 3apa>KeHHH. ΠρΗ BblBBJieHHH ρ33ΜΗΟ>ΚβΗΗΗ BHpyca B OnyXOBeBOH TKaHH nojryHeHHbie b oth MaKCHMajībHoro pa3MHO>KeHHB ueHTpi^yrHpyK)T πρκ 3000 o6/mhh b TeneHHe 20 MHHyr.
AiianTaunio KyjibTypw προβΟΛΗΤ no cjieayioiaeH cxeMe: penpo,ayuHpoBaHHbiH b onyxojieBofi TKaHH BHpyc naccHBHpyeTCH (pa3MH05KaeTC«) b TecT-KyjibType φπ6ρο6ιΐ3θτοΒ 3M6pHOHa nejioBeKa h BHOBb naccHBHpyercH nepe3 TKaHb onyxojiH. Πρπ stom npoBoaHTca 3-10 nocjie^oBaTejibHbDc HepeaoeaHHbK nacca^cefi b KyjibTypax nepe^cMBaiomeH TKaHH ot HHaHBHflyajibHbix onyxojieH h b TecT-KyjibType.
MaTOHHbift LirraMM BHpyca xpaHHTca b 3aMopo>KeHHOM BHfle npH TeMnepaType /-20°C/ - /-70°C/.
Pa3MHoxceHHe uiTaMMa Be,ayT Ha KyjibType φκ6ρο6;ΐ3<ΠΌΒ 3M6pHOHa HejioeeKa ao THTpa 5 - 7 lg TLm50/0,l mji Ha nimTejibHOH cpe,ae 199 6e3 CbiBOpOTKH c noēaBjieHHeM aHTH6HOTHKOB. neHHUHJIJIHH 100 efl/MJl, CTpenTOMHUHH 50 efl/MJI. B cpe;iy Moacer 6brrb aoēaBJieH HHjjHKaTop ρΗ-φβΗΟΛΟΒωβ KpacHbifi c KOHueHTpauHeH 0,002%. )ΚΗΰΚΒΗ φβ33 ΗΗφΗΗΗρ0Β3ΗΗ0Η KyjIbTypbI φπ6ρθ6Λ30ΤΟΒ 3M6pHOHa HejioeeKa nocjie ποληοη aereHepauHH κπβτοκ ocBerjmercH ^eHτpHφyΓHpoBaHHβM npH 3000 o6/mhh B ΤβΗβΗΗβ 2- MHH.
IlojiyHeHHbiH HMMyHOCTHMyjiHTop npoTHBOonyxojieBoro ΛβΗΟΤΒΗΛ npeacTaBjiaer co6oh cTepHJibHyio >KH,aKOCTb po30Boro UBera. OHa φacyeτcJ^ b Φιήκοημ no 2 mji (2 * 107 T/m 50) - ao3a aju οληοη ηηβοκηηη. IlpenapaT xpaHHrca b 3aMopo*eHHOM BHae.
IlojiyHeHHbiH HMMyHOCTHMyjurrop npHMeHajica y 6ojibHbix 3jiOKaHecrBeHHOH MejiaHOMOH kojkh (Ti.3‘N0-Mo) nocjie XHpyprHHecKoro ynajieHHH nepBHHHOro onara, hjih nepBHHHOTO OHara BMeCTe C perHOHapHbIMH .JIHMφoy3JIaMH. ΠρΗΜβΗβΗΗβ npenapaTa HaHHHaerrca c 2 - 4 Heaejib nocjie onepauHH napeHTepanbHO (BHyTpHMbimeHHo) β ΒβρχΗΗΗ Hapy>KHbiH KBaapaT ηγολημηοη o6jiacTH.
CxeMa πρΗΜβΗβΗΗΛ npenapaTa cjieayiomaa: nepebie τρκ Mecaua τρκ e>Ke,aHeBHbie •j HHbeKUHH no 2 mji (2 x 10 TlļZ^o Bnpyca), nocjie Kaacaoro Kypca nepepbiB β τρΗ Heaejrn, noc/ie/iyK)mne τρκ Mecaua no oahoh HHbeKUHH eaceMecaHHO. īlocjie 3τογο cjiejiyeT TpexMacaMHbiH nepepbiB c ποΒτορβΗΗβΜ eaceMecHHHbix ηηέθκηηη b 9 - 12 Mecan noc^eonepaunoHHoro nepnojia 6 ΠρΗΜβΗβΗΗε npenapaTa momcct 6brn> HanaTo nepeA yAaJieHHeM nepBHHHoro onara onyxojiH 3a 1 - 2 He^ejiH: TpexKpaTHoe e>KeAHeBHoe BBeaeHHe no 2 mji (2 * 107 TlļO^o BHpyca).
Bo3MoaceH 6ojtee AAHTenbHbin οροκ npHMeHeHna npenapaTa b nocaeonepauHOHHOM nepHO^e ao 2 - 3 jieT c ποΒτορβΗΗβΜ e>KeMecBHHbix HHteKUHH no 2 mji. BBeAeHHe npenapaTa npaKrnnecKH He Bbi3biBaer no6oHHbix HBJieHHH.
Hnace npHBojurrca pe3yjibTaTbi KjiHHHnecKHx ηοπηταηηη 3aaBjweMoro HMMyHOCTHMyAHpyiomero npenapaTa (HCBI1 - HMMyHOCTHMyjnrrop BnpycHOH npnpoAbi), npenapaTa SaKTepnajībHOH npnpoAbi (npenapaT C.P.- Corynebacterium Parum) n xHMHHecKoro npenapaTa neicapHca (jieBOMH30jia) y 6oAbHbix 3 jio KaHecTBeHHOH MeJiaHOMOH. IIpenapaT Aexapnc npHMeHHACA no cjieAyK)men cxeMe: Ta6jieTKH napeHTepajībHo exceHeAejibHO 2 pa3a c HHTepBajiOM b 3 αηα b TeneHHe 8 Mecauee, ηβηηηβη co 2 - 4 HeaejiH nocjie yAajieHHa onyxoAH. IIpenapaT C.P. npHMeHJuica no cxeMe: HMMyHOCTHMyjwnHa HaHHHajicb nepe3 1 - 4 HeaeJiH βηυγρηβθηηο nocae paaHKanbHOH onepauHH. IlepBbie 5 Anen npenapaT bboaat BHyTpHBeHHO 1 - 4 μγ b AeHb πρπ B03pacTajomeH A03npoBKe. B nocAeAjnomeM b TeneHHe roAa npenapaT ββοαητ ποακο>κηο ejfceHeAejibHo no 1 mji b 4-χ τοηκαχ b o6jiacTH acHBOTa. IIpoaHajiH3HpoBaH MaTepnaji aab 6oAbHbix, κοτορωβ HaxoAHjiHCb ποα Ha6jnoAeHHeM He MeHee 3-x Aer.
HnAce b TaēnHue 1 npHBeAeHbi AaHHbie no BbDKHBaeMOCTH h xapaicrepy τβπβΗΗΗ npouecca y 6oAbHbix MeAaHOMOH kojkh nocAe paAHKajībHofi onepanHH.
Ta6jiHna 1
Xapaicrep HaSmoAeHHB HMMyHOCTHMyjTKTOpbI TOAbKO onepauHA C.P. TleKapnc HCBn BbDKHBaeMOCTb 13:21 22:28 21:25 54,5% 62% 78,6% 84% CTa6HAH3auHii npouecca 10:21 17:28 . 16:25 25,7% 47% 60,7% 64% B Ta6jinue b MHCjnrrejie yKa3aHO hhcjio 6oAbHbix c nojiojKHTenbHbiMH ποκ33ΑτβΑΗΜΗ, a b 3HaMeHarejie - o6mee hhcjio Ha6AiOAaeMbix 6ojibHbix. 7 LV 12861
TaKHM o6pa30M, aaHHbie noica3biBaK>T, mto HamiyHiiiHe ziaHHbie no BbDKHBaeMocTH nojiyneHbi πρπ πρημβηβηηη 3aHBjiaeMoro HMMyHOCTHMyjnrropa Ha ochobc KyjibTypbi 3HTepOBHpyCOB. B Ta6jiHue 2 npeucTaBJieiia αηη3μηκβ CMepTHOCTH 6ojibHbix MejiaHOMOH kojkh nocne xnpyprHHecKoro JieHeHHH h HMMyHOCTHMyjiHUHH.
Ta6jiHua 2
Ha6jnoaaeMaa YMepjiH b τβπβΗΗβ rpynna 1-ro roaa 2-x jieT 3-x Jier C.P 1:21 6:21 8: 21 5% 29% 38% fleKapHC 2:28 6:28 6:28 7% 21% 21% HCŪB 0:25 2:25 4:25 0% 8% 16% TojibKO onepauHa 54,5% B HHCJiHTejie yKa3aHO hhcjio yMepuiHx, a b 3HaMeHaTejie o6mee hhcjio Ha6jnoaaeMbix 6ojibHbix.
Vh aaHHbrc TaGjmubi cjieuyeT, hto HMMyHOCTHMyjiHUHH 3aHBJineMbiM npenapaTOM cymecTBeHHo noBbiiuaeT BbDKHBaeMocrb, Taic npH πρΗΜβΗβΗΗΗ npenapaTa b nepBbin roa He yMepjio hh ohhoto 6ojibHoro, b to BpeMH icaic npH jieneHHH apyrHMH npenapaTaMH yMepjio cooTBercTBCHHO 5% h 7% ot o6mero nncjia 6ojibHbix.
Pa3HHua b CMepTHOCTH Ha6jnoflaerca h nepe3 2 roaa, no cpaBHOHHio c HamiyHiiiHM no aaHHbiM npenapaTOM aeicapnc pa3HHua b CMepTHOCTH cocraBjineT 1,3 pa3a. 3aaBJweMbiH npenapaT yMeHbtuaeT nacTOTy nporpeccnpoBaHHB npouecca nocne paaHKajībHofi onepauHH. HHxce b Ta6jiHue 3 npnBeaeHbi aaHHbie no nacroTe nporpeccnpoBaHHH npouecca y 6ojibHbix MejiaHOMon kojkh nocjie pauHKajībHofi onepaunn h nMMyHOCTHMyjijnjHn.
Ta6jinua 3
BpeMH npenapaT TOJIbKO onepauHH CP fleKapHc HCITB 3 roaa 11:21 11:28 9:25 74,3% 53% 39% 36% B HHCJiHTejie yKa3aHO hhcjio 6ojibHbrx c nporpeccHpOBaHHeM npouecca, b 3HaMeHaTejie - o6iuee hhcjio Ha6jnoaaeMbix 6ojibHbix. 8
KaK bhuho H3 TaojTHiibi, caMoe MeoneHHoe nporpeccnpoBaHHe npouecca HaSjnoaaeTca npn npHMeHeHHH 3aaBjiaeMoro npenapaTa.
Xapaicrep aHCceMHHauHH onyxojin - MeaaHOMbi ko>kh noc;ie panHKajībHofi onepauHH b 33βηοημοοτη ot npHMeHaeMoro HMMyHOCTHMyjiaTopa πρΗΒβαβΗ b Ta6nHue 4. T a6jiHua 4 HMMyHO- M e τ a c T a 3 bl CTHMyaaTop PeuHaHBbi ποακοχίΗωε B JIHM(ļ)0-y3.nax B αβΓΚΗΧ B M03ry C.P. 1:11 4:11 6:11 7:11 3:11 9% 36% 55% 63% 27% /ļeicapHC HeT 1:8 4:8 2:8 1:8 12,5% 50% 25% 12,5% HCnB ΗβΤ 3:9 4:9 1:9 1:9 33% 45% 11% 11% B MHCJiHTēJie yKa3aHO hkcjio 6ojibHbix c peunjiHBaMH (MeTacra3aMH), b 3HaMeHaTejie - o6mee hhcjio Ha6jnoaaeMbix 6oabHbix. H3 ,aaHHbix Ta6jiHiļbi 4 βηληο, ητο πρπ npHMeHeHHH 3aaB;raeMoro npenapaTa b ochobhom o6pa3yK)Tca noziKOjKHbie MeTacra3bi h MeracTa3bi b JIHMφoy3JIax, κοτορΜβ cpaBHHTejibHO aenco o6HapyxcHBaiOTC« h yaaaaiOTca. MeTacra3bi b jieriooc o6pa3yioTca 6 pa3 h b 2,5 pa3a peoce, neM npn npHMeHeHHH apyrnx H3BecTHbix npenapaTOB. B Ta6jiHue 5 npe.acTaB.jieH xapaicrep TeneHHH 3a6ojieBaHHa yMepmHx 6cuibHbix.
Ta6aHiia 5
Tpynna Ha6aioaaeMbix Hhcjio 6ojrbHbix iJjTHTejIbHOCTb cTa6HaH3auHH (Mec.) BpeMa aHCceMHHauHH (Mec.) ^ĻiHTeubHOCTb )KH3HH (Mec.) C.P. 9 13 9 22 /ieicapHc 6 10 5 15 HCBI1 10 17 12 29 H3 aaHHbix Ta6jiHHbi 6 caeayer, hto 3aaB;meMbiH npenapaT cymecTBeHHO yaaHHaeT BpeMa CTa6HaH3auHH, epeina aHCceMHHauHH h aaHTeabHOCTb >kh3hh Ha 12 Mecjuiee no cpaBHeHHio c aeKapHcoM h Ha ceMb MecaueB no cpaBHeHHio c npenapaTOM Ha ocHoee Corynebacterium Parum. 9 LV 12861
Hime b Ta6jiHue 6 npHBeneHbi aaHHbie no BbiacHBaeMOCTH 6ojibHbix paKOM )KejiyziKa, paaHKajībHO onepnpOBaHHbix Ha ΠΙ cranHH 3a6ojieBaHHa.
Ta6jiHua 6
Bpevia BbUKHBaeMOCTb (nacTOTa b %) Ha6jnoiieHiia HCBFI OnepauH» 2 roaa 15:21 71,41 45,8 5 Jier 10:21 24,2 47,6 B HHCJiHTejie yKa3aHO o6mee hhcjio >κηβμχ 6ojibHbix, a b 3HaMeHaTejie o6mee hhcjio Ha6jiK)itaeMbrx 6ojibHbix. H3 flaHHbrx Ta6jiHUbi cjieayeT, ητο πρκ npHMēHeHHH 3aKBXiaeMoro npenapaTa nacTOTa BbDKHBaeMOCTH noBbimaerca b 1,5 - 2 pa3a no cpaBH6HHK> c TOJibKO onepaunoHHbiM jieneHHeM. Ηπ>κβ b Ta6jiHue 7 npnBeneHbi ziaHHbie no BbKKHBaeMOCTH 6ojibHbix paKOM npaMofi KHuiKH nocjie paaHKajībHofi onepanHH.
Taēanna7
Bpe\w BbixcHBaeviocTb (nacroTa b %) Ha6jnoneHHa Onepauna + HCBII OnepanHa 10:14 5 jieT 71,2 58,2 B MHcauTejie yKa3aHO hhcjio >κηβμχ 6ojibHbix, a b 3HaMeHaTejie - o6mee hhcjio Ha6jnojiaeMbix 6ojibHbix.
Kax bhjiho H3 πρΗΒβΛβΗΗΟΗ TaSiiHiibi, πρπΜβΗβΗΗβ 3aHBjiaeMoro npenapaTa noBbiuiaeT BbDKHBaeMOCTb Ha 14%. HHace npHBO^aTCH aaHHbie no kohtpojiio HMMyHOJiorHHecKoro CTaTyca npn npneMe 3aaBjiaeM0ro HMMyHOCTHMyjiaTopa (HCBFI).
I PeaKUHa Γ3Τ Ha onvxojieaccoiiHHpoBaHHbiH MejiaHOMHbin aHTHreH
HacroTa BCTpeHaeMOCTH nojioacHTejibHOH peaKUHH Γ3Τ y 6ojibHbix, nojiyHHBuiHx HCBFI, cymecTBeHHO He MeHaerca b nepBbie 6 Mecanee (50 - 60%). Πρπ bo3o6hobjichhh CTHMyjiauHH (9-12 Mecanee) aaHHbiH noKa3aTejib yBejiHHHBaerca y 10% 6ojibHbix, T.e. 10
HacTOTa BcrpeHaeMOCTH HopMajibHbix peaKUHH Γ3Τ Ηβ MeHHeTca hnu yBejiHHHBaeTca b Tenemie cthmyjimuhh HCITB. ΠρΗ πρΗΜβΗβΗΗΗ ueKapnca nacroTa BcrpeHaeMOCTH HopManbHbrc peaKUHH Γ3Τ MeHHerca, nepe3 2 Mecaua y 35% 6ojibHbix uaHHaa peaKUHH He npoHBJiaerca V pana 6ojibHbix nacroTa BcrpeHaeMOCTH uaHHofi peaKUHH ρβ3κο Me«weTca (20 - 35%). riocKOJibKy peaKUHH Γ3Τ OTpaacaeT cnocoēHOCTb opraHH3Ma pacno3HaBaTb, pearHpOBaTb h orropraTb onyxojieaccouHHpoBaHHbm aHTHreH, το cTa6HJiH3amw noKa3aTeJia hjih ero yBejiHHeHHe HBjiaeTCH 6/iaronpRHTHbiM nproHaKOM, a pe3KHe KOJie6aHHH h CHHaceHHe uaHHOH peaKUHH - He6nnronpHHTHbifi npH3HaK coctohhhh HMyHHOH CHCTeMbI BO BpeMfl HMMyHOCTHMyJIHUHH. TaKHM 06pa30M, no UaHHOMy noKa3aTejno HCIIB jiyHuie npenapaTa «zieKapnc».
Z. PliilJI Ha onvxojieaccouHHpoBaHHbiH MejiaHOMHbiH aHTHreH IIpHMeHeHHe HCBII b nocneonepauHOHHOM nepnone He Bbi3biBaer pe3KHx KOJie6aHHH peaKUHH. HacroTa BbiHBjiaeMOCTH uaHHoft peaKUHH no xoay HMMyHOCTHMyjWUHH ΗΜββΤ ΤβΗΛβΗΠΗΙΟ B CTOpOHy yBejIHHeHHH B rpynne 60JIbHbrX, nOJiyHHBU!HX HMMyHOCTHMyjIHUHK) UeKapHCOM, HacTOTa BblHBJlfleMOCTH peaKTHBHOCTH no Mepe CTHMyjiauHH yMeHbmaeTCH ot 80 ao 30%, T.e. b KOHue Kypca ToabKO y 30% 6ojibHbix jieiĪKOUHTbi κροΒΗ y3HaiOT h pearHpyioT Ha MenaHOMHbiH aHTHreH. PliilJI TaK ace KaK peaKUHH Γ3Τ OTpaacaeT cnoco6HOcn> Τ-λημΦοηητοβ y3HaBaTb h pearapoBaTb Ha onyxojieaccouHHpOBaHHbiH aHTHreH. Hcne3HOBeHHe, CHHaceHHe uaHHOH peaKTHBHOCTH cjieryeT paccMaTpHBaTb KaK noKa3aTenb CHHaceHHH npoTHBOonyxojieBOH pe3HCTeHTH0CTH.
CneuyeT OTMeTHTb, hto nocne npeKpameHHH cTHMyjwuHH ueKapHCOM aaHHbiH noKa3aTejib uocroraeT ηοχοληογο ypoBHH. 3. ΗηΓΗΟΗΤΟΡ nPHJIHnaHHH JieHKOUHTOB B CbIBOpOTKe κροΒΗ
Bo epeMH HMMyHOCTHMyxwuHH HCBn BbiHBJieHHe aaHHoro noKa3aTejta yBejiHHHBaercH ot 35% b Hanane Kypca no 80% b KOHue Kypca CTHMyjiHUHH. B rpynne, nojiyHaBuieH ueKapnc, nacTOTa BCTpeHaeMOCTH naHHoro napaMeTpa no Mepe CTHMyjmuHH yMeHbuiaercH ot 40% b Hanane Kypca uo 20% b KOHue xypca HMMyH0CTHMyjwuHH. Ηηγη6ητορ npHJiHnaHHH /ιθηκοπητοβ, o6HapyacHBaeMbix b ΡΠΤυΐ, BbiHBJiaeTCH y 3nopoBbix jnoueH ot 60 ao 80% cnyHaeB. TaKoii ace noKa3aTejib y 6ojibHbix MenaHOMofi nocjre paaHKajībHofi onepaunn, nojiyHHBuiHx HCBn h npH cra6HjiH3auHH npouecca. Ηηγηοητορ Hcne3aeT bo BpeMH aHcceMHHauHH npouecca, no3TOMy npHcyTCTBHe 11 LV 12861 HHrH6HT0pa npHJIHriaHHfl JieŪKOUHTOB B CbIBOpOTKe HBJiaeTCH OJJHHM H3 napaMeTpOB HopMajībHoro HMMyHOJiorHHecKoro CTaTyca. IIoHBJieHHe ero y 45% 6ojibHbix, CTHMyjiHpoBaHHbix HCBII, «BjmercH noKaaarejieM nojiojKHTejibHoro 3φφβκτΒ HMMy HOCTHMyjlHUHH.
CpaBHHTejibHO b rpynne 6ojibHbix, nojiyHHBiiiHx zieKapnc nocjie 4 MecaueB CTHMyjwuHH ηηγη6ητορ b κροΒΗ o6HapyxcHBaerca TOJibKO y 20% 6ojibHbix. 4. EjIOKHpVIOmHH φΒΚΤΟΡ CbIBOpOTKH KpOBH. BbLHBJiaSMblH B PļlTUI Ejiokhpjtoihhh φΒκτορ OTpaacaeT cocToaHHe 6jioKaabi HMMyHOKOMneTeHTHbix KJieroK, yMacTByK3iiļHX b npoueccax npOTHBOorryxojieBoro HMMyHHTera. flaHHblfi φaκTOp BblHBJIHCTC# nOCJie yaaJieHHB nepBHHHOro OHara MCJiaHOMbl ποητη y 25 - 30% 6ojibHbix. BcjiencTBHe πρΗΜβΗ6ΗΗΗ HCBII aaHHbifi φaκτop BbiHBJMercH Ha 6-OH Mecau HMMyHOCTHMyjWUHH TOJibKO y 10% 6oJIbHbIX.
EjIOKHpyK)mHH φακτορ B CbIBOpOTKe KpOBH TaiOKe CHHJKaeTCH B T6H6HH6 2-Χ nepBbIX MeCHIieB HMMyHOCTHMyjWU[HH JieKapHCOM H BbLHBJIBeTCH y 10% SojIbHbDC, OflHaKO, Ha 6-oii Mecau HMMyH0CTHMyjiaijHH 6jiOKHpyioinHH φ3κτορ o6Hapy»cHBaeTCH y 30 - 40% 6ojibHbix, npn 3tom o6HapyxcHBaeTca y τβκηχ 6ojibHbix, κοτορωβ nocjie ynajieHiM orryxojiH 6jiOKHpyioiuero φaκτopa b κροΒΗ He HMejin. 5. ripOTHBOBHpVCHbie aHTHTejia B CbIBOpOTKe KpOBH B nepBbie Mecaubi πρκ HMMyHOCTHMyjiHiiHH HCBII b cbieopoTKe κροΒΗ ρβ3κο B03pacTaiOT npoTHBOBHpycHbie aHTHTejia, o6HapyxcHBaeMbie b peaxuHHx HeHTpajiH3auHH h τορΜωκβΗΗΗ reMarjuoTHHaiļHH. Πρπροστ BHpycHeihpajiH3yiomHx aHTHTeji b sto BpeMH aocTHraeT rmp ot 1:20 λο 1:5000-10000. ΠρΗ npeKpameHHH nMMyHOCTHMyjwuHH (6-9 Mecaiiee) THTpbi aHTHTeji najiaiOT h cTa6HjiH3HpyK>TCH πρκ ο6ηοβλ6ηηη HMMyHOCTHMyjwiiHH (9 - 12 Mecanee).
TaKHM o6pa30M b opraHH3Me 6ojibHbix προκοχοΛκτ βκτηβημη BHpycHbiii HMMyHoreHe3. BnpycHbiH HMMyHoreHe3 aBJinerca GjiaronpmrrHbiM cpoKOM npoHBJieHHB npOTHBOonyxojieBoro HMMyHHTeTa nyreM BOCCTaHOBJieHHB h HopMajiH3aijHH npoueccoB, 3a6^0KHpoBaHHbix orryxojieBbiM poctom.
TaKHM o6pa30M, npHMeHeHHe HCBII b nocjieonepauHOHHOM nepnojie nocjie panHKajībHoro y,aajieHHfl nepBHHHOro onara MejiaHOMbi kojkh cTa6HjiH3HpyeT hjih aKTHBHpyeT HMMyHHbie peaKLiHH opraHH3Ma. 12 Πρκ 3τομ He Ha6jnoaaiOTca λβλθηηλ nepecTHMyjwuHH, ayroHMyHHbix peaKUHH. IIoKa3aTeaH ημμυηολογμηθοκογο (rraTyca cBHjieTejibCTByiOT 06 otcjtctbhh tokchhcckhx 3φφβΚΤΟΒ npH HJTHTejIbHOM napeHTepaJIbHOM ΠρΗΜβΗβΗΗΗ HCBn. 3aaBJiaeMbifi HMMyHOCTHMyjwTOp Ha ocHoee anaToreHHoro aaarrrHpOBaHHOro κ onyxojiH uiTaMMa 3HTepoBHpycoB Picornaviridae Enterovirus rana ECHO 3φφβκτΗΒβΗ npa nonaBjieHHH pocra onyxojieH. /ļaHHbiH τηπ BnpycoB He HMeer οβοποπβκ, BKJQOHaiomHx aHTHreHbi KneroHHoro npoHCXO)KfleHH», HHflyuHpyiomHX SBJieHne ayroHMMyHirreTa.
KpoMe Toro, 3τοτ τηπ BHpycoB o6jiaaaer reHerHHecKOH 6e3onacHocrbio, o6ecneHeHHofi opraHroaunefi reHOMa He HHTerpHpyK>merocs c KJieroHHbiM reHOMOM h He ^aiomero peicc>M6HHauHH c reHOMaMH apyrHX BHpycoB.
Pa3pa6oTaHHbiH cnoco6 nojiyHeHHa HMMyHOCTHMyjurropa o6ecneHHBaer nojiyHeHHe npenapaTa c HaH6ojibineH aKTHBHocrbio. 3aaBjweMbiH HMMyHOCTHMyjurrop 3κγηβηο nonaBJiser poer onyxojiH npH peimarae, yfljiHHHer BpeMa CTa6HjiH3aiļHH Me»cfly peuHflHBaMH, yBejiHHHBaer BpeMa AHeceMHHauHH. KpoMe Toro, npH peuHflHBax b ochobhom o6pa3yiOTca noflKO>KHbie Meracra3bi b jiHv^oy3Jiax, Kcrropbie cpaeHHTejibHO Jierico yaajiHTb. 13 LV 12861 OOPMYJIA Η30ΕΡΕΤΕΗΗΛ 1. HMMyHOCTHMyjwTOp προτΗΒΟΟπγχοπβΒΟΓΟ ΛβΗΟΤΒΜΛ, BKJiHD4aK>mHH anaToreHHyio BHpycHyio KyjibTypy, OTjiHMaioiuHHCJi τβΜ, hto c uejibio ποβηπι6ηηη 3φφβΚΤΗΒΗΟΟΤΗ ĪIOflaBJieHHfl pOCTa OnyXOJlH npH nJIHTeJlbHOM HCn0JIb30BaHHH, B KanecTBe KyjibTypbi Hcnojib3yiOT anairrHpoBaHHbiH κ onyxojiH ιπτβμμ 3HTepoBHpycoB Picornaviridae Enterovirus rana ECHO, BbinejieHHbiH H3 KHiueHHHKa nejiOBeKa c thtpom Ha mohocjiohhoh KyjibType φH6po6JIacτoB 3M6pHOHa nejiOBeica paBHbiM 5 - 7 lg 11123,50/0,1 mji.
2. HMMyHOCTHMyjWTOp ΠΟ Π. 1, OTJIHHaiOIHHHCH ΤβΜ, HTO UITaMM 3HTepoBHpycoB BbijiejieH H3 KHiueHHHKa peēeHKa b B03pacTe 2-5 jier. 3. Cnoco6 jum nojiyHeHHH HMMyHOCTHMyjiaTopa no π. 1 nyreM BbmejieHira anaTOreHHOH BHpycHofi icyjibTypbi, naccHBHpoBaHHJi ee b mohocjiohhoh KyjibType KjieTOK c nocjiejjjTomHM ee pa3MH0>KeHHeM b mohocjiohhoh KyjibType ιοιβτοκ h oTflejieHHeM pa3MH0*:eHH0H BHpycHOH Kyjibrypbi, OTjiHnaiomHHca τθμ, hto anaToreHHyio KyjibTypy 3HTepoBHpycoB BbiaejunoT H3 κηιιιθηηηκβ HejioeeKa, OTānpaiOT BHpycHyio KyjibTypy, HMeiomyK) cponcreo κ onyxojiH, a naccHBHpoBaHHe npOBOfljrr Ha onyxojieBbix τκβηλχ pa3JiHHHbix 6ojibHbix, nocjie nero προβοΛΛτ pa3MHoaceHHe naccHBHpoeaHHoro uiTaMMa Ha KyjibType φH6po6JIacτoB 3M6pnoHa nejiOBeKa no THTpa 5-7 lg ΊΠ1Ζ350/0,1 mji. LV 12861 ΑΗΗΟΤΑΙ1ΗΛ HMMyHOCTMMynynOp npoTMBOonyxoneBoro fleticTBUfl n cnocoč ero nonyMeHnn HMMyHocTHMyjisrrop npoTHBOonyxojieBoro fleficTBua npeflCTaBJMer co6oii anaToreHHyio BHpycHyio KyjibTyTy, KOTopas nojryHeHa nyreM aaanTHpoBaHRa b onyxojib ιιιτεμμε 3HTepoBHpycoB Picnoviridae Enterovirus rana ECHO, o6hhho BbiaejiaeMoro H3 KHUieHHHKa nejiOBeKa. OniHHHTejibHbiM HBjuferca to, hto uiTaMM 3HTepoBHpycoB BbiaejieH H3 KHineHHHKa pe6eHKa b B03pacre 2-5 jier, a naccHBHpoBaHHe npoBeaeHo Ha onyxoneBbix TKaHax pa3JiHHHbix 6ojibHbix c nocjieziOBaTejibHbiM pa3MHoxceHneM naccHBHpOBaHHoro uiTaMMa Ha KyjibType φΗ6ρο6ϋ3οτοΒ 3M6pHOHa HejioeeKa.
Pa3pa6oTaHHbiH cnoco6 nojiyHeHna o6ecneHHBaer MaKCHMajibHyio HMMyHOCTHMyjiHpyiomyio aKTHBHOCTb npenapaTa. HMMyHOCTHMyjWTop aiorHBHO npoTHBOfleHCTByer peiļHjiHBaM onyxojiH, yBejTHHHBaer BpeMH AHCCeMHHaiļHH, ΠρΗΗβΜ npH peUHflHBaX o6pa3yiOTCH TOJIbKO Meracra3bi noAKoacHbie η b πΗΜφο^πβχ, κοτορωβ HerpyflHO yAajiHTb.

Claims (3)

  1. LV 12861 IZGUDROJUMA FORMULA 1. Imūnstimulātors ar pretaudzēja darbības aktivitāti, kas satur apatogēna vīrusa kultūru, atšķiras ar to, ka vīrusa kultūra ir iegūta, adaptējot audzējā ECHO enterovīrusa celmu Picomaviridae Enterovirus, izdalītu no cilvēka zarnu trakta, kura titrs cilvēka embrija fibroblastu vienslāņft kultūrā ir 5 - 7 lg CPD50/0,1 ml.
  2. 2. Imūnstimulātors saskaņā ar 1.punktu, atšķiras ar to, ka enterovīrusa celms izdalīts no 2 - 5 gadu veca bērna zarnu trakta.
  3. 3. Imūnstimulātora iegūšanas paņēmiens saskaņā ar 1. punktu, kas ietver apatogēnu vīrusu kultūras izdalīšanu, pasažējot vienslāņa šūnu kultūrā ar secīgu savairošanu vienslāņtL šūnu kultūrā, atšķiras ar to, ka apatogēno vīrusu izdala no cilvēka zarnu trakta, bet pasažēšanu izdara uz dažādu slimnieku audzēja audiem ar secīgu pasažētā celma savairošanu cilvēka embrija fibroblasta kultūrā līdz titram 5 - 7 1^ CPD50/0,1 ml.
LVP-02-108A 2002-06-14 2002-06-14 Imūnstimulators ar pretaudzēja aktivitāti un tā iegūšanas paņēmiens LV12861B (lv)

Priority Applications (7)

Application Number Priority Date Filing Date Title
LVP-02-108A LV12861B (lv) 2002-06-14 2002-06-14 Imūnstimulators ar pretaudzēja aktivitāti un tā iegūšanas paņēmiens
EA200500014A EA007839B1 (ru) 2002-06-14 2003-06-13 Иммуностимулятор противоопухолевого действия и способ его получения
TR2018/09382T TR201809382T4 (tr) 2002-06-14 2003-06-13 Antineoplastik etkiye sahip immünostimülatör ve söz konusu immünostimulatörün üretilmesine yönelik usul.
ES03733607.0T ES2678053T3 (es) 2002-06-14 2003-06-13 Inmunoestimulante que tiene una acción antineoplásica y procedimiento para producir dicho inmunoestimulante
EP03733607.0A EP1537872B1 (en) 2002-06-14 2003-06-13 Immunostimulator having antineoplastic action and method for producing said immunostimulator
AU2003241866A AU2003241866A1 (en) 2002-06-14 2003-06-13 Immunostimulator having antineoplastic action and method for producing said immunostimulator
PCT/LV2003/000006 WO2003105875A1 (fr) 2002-06-14 2003-06-13 Immunostimulateur presentant une activite anticancereuse et procede de preparation correspondant

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
LVP-02-108A LV12861B (lv) 2002-06-14 2002-06-14 Imūnstimulators ar pretaudzēja aktivitāti un tā iegūšanas paņēmiens

Publications (1)

Publication Number Publication Date
LV12861B true LV12861B (lv) 2002-10-20

Family

ID=19735339

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-02-108A LV12861B (lv) 2002-06-14 2002-06-14 Imūnstimulators ar pretaudzēja aktivitāti un tā iegūšanas paņēmiens

Country Status (7)

Country Link
EP (1) EP1537872B1 (lv)
AU (1) AU2003241866A1 (lv)
EA (1) EA007839B1 (lv)
ES (1) ES2678053T3 (lv)
LV (1) LV12861B (lv)
TR (1) TR201809382T4 (lv)
WO (1) WO2003105875A1 (lv)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2826856T3 (pl) * 2013-07-16 2016-06-30 Sia Latima Genetycznie stabilny onkolityczny wirus RNA, sposób jego wytwarzania i zastosowanie
GB201808500D0 (en) 2018-05-23 2018-07-11 Ditesan Ltd Virus and virus use
WO2020035423A1 (en) 2018-08-13 2020-02-20 Ditesan Ltd. Combination therapy of cancer by administrating echo-7 virus and a pharmaceutically effective anti-cancer drug

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US435914A (en) * 1890-09-09 Device for replacing cars on railroad-tracks
US4315914A (en) * 1980-04-04 1982-02-16 Seiji Arakawa Pharmaceutical compositions useful as cellular immunopotentiator and antitumor agent and process for production thereof
AUPQ425699A0 (en) * 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same

Also Published As

Publication number Publication date
EP1537872A4 (en) 2008-03-12
TR201809382T4 (tr) 2018-07-23
AU2003241866A1 (en) 2003-12-31
WO2003105875A8 (en) 2005-03-24
ES2678053T3 (es) 2018-08-08
WO2003105875A1 (fr) 2003-12-24
EP1537872A1 (en) 2005-06-08
EA007839B1 (ru) 2007-02-27
EA200500014A1 (ru) 2005-06-30
EP1537872B1 (en) 2018-05-09

Similar Documents

Publication Publication Date Title
KR101051535B1 (ko) 세포 증식의 소형 유기 분자 조절물질
AU2002231049B2 (en) Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
KR101320718B1 (ko) 세균 감염 치료용 조합 약제
EP0778022B1 (en) Use of rifamycin derivatives for the treatment of chlamydia infectous diseases
HU220669B1 (hu) Eljárás diabéteszes szövődmények kezelésére vagy megelőzésére szolgáló gyógyászati készítmények előállítására
EA200300316A1 (ru) Производные глюкопиранозилоксибензилбензола и содержащие их лекарственные композиции
AU8872991A (en) Novel 5-iodo-6-amino-1,2-benzopyrones and their analogs useful as cytostatic and antiviral agents
EP1906955A2 (en) Use of thiazole derivatives and analogues in the treatment of cancer
LV12861B (lv) Imūnstimulators ar pretaudzēja aktivitāti un tā iegūšanas paņēmiens
GB2118540A (en) Anthracycline glycosides
RU98102156A (ru) Производные тритерпена и фармацевтические композиции для лечения заболеваний печени
NO974076D0 (no) Reduksjon av infarktvolum ved å anvende citicolin
AU2005206560A1 (en) Bis-indole pyrroles useful as antimicrobials agents
DK0733035T3 (da) Tricykliske derivater og farmaceutiske præparater, der indeholder dem
AU2001278463B2 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and topoisomerase i and ii inhibitors
US5962480A (en) Drug for ameliorating brain diseases
AU2001278463A1 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and topoisomerase i and ii inhibitors
ZA200507122B (en) Pyridylsufonamido pyrimidines for treating diabetic neprhopathy
DE2139272A1 (de) Cephalosponnverbindungen
US7642229B2 (en) Pharmaceutical composition and a product which includes a substituted acryloyl distamycin derivative, an antimicrotubule agent and/or an antimetabolite
US6046041A (en) Method for producing marine-derived compounds and novel compounds produced therefrom
US20030040491A1 (en) Use of pentosan polysulfate to treat certain conditions of the prostate
DE4121468A1 (de) Antivirale substanzen und diese enthaltende arzneimittel
JP2004035475A (ja) ＴＧＦβ作用抑制剤
AU2001267553A1 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives, taxanes and/or antimetabolites